Please assess the completion status of the following clinical trial:

Trial Title: GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance Tomography (MRT)~* Patients who need by judgement of a clinical neurologist or neurosurgeon surgical removal of the blood clot due to its space-occupying effects~* Age greater or equal 18 years for men~* Age greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or surgical sterilisation at least 3 months before study start)~* For all other women age greater or equal 50 years with last menstrual bleeding at least one year before study start~* Minimum hematoma diameter of 2 cm as measured in baseline CCT or MRT~* Signed, written informed consent of patient or consent/assertion from the patient's legally acceptable representative/affiliated if the patient is unable to provide informed consent~Exclusion Criteria:~* Participation in any other clinical trial within the past 3 months or ongoing~* Occurrence of inconsistency with initial diagnosis at baseline during surgery of the patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or trauma~* Patients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into the brainstem~* Patients with severe pre-existing physical or mental disability or severe comorbidity that interferes with the assessment of outcome~* Allergy to contrast media (MRT)~* Acute infection~* Muscular, neurological, or vascular insufficiency of the respective tissue~* Polypropylene incompatibility~* Acute immunosuppressive medication~* Patient after organ transplantation~* Patient with immune depression~* Patients with a high probability of spontaneous recovery or showing rapidly improving signs~* Patients with extensive intracranial hemorrhages or with deep hemispheric localisation of the clots~* Patients whose diagnosis of ICH is uncertain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLP-1 CellBeads (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).